Syndex Bio Launches mcPCR Platform to Transform Gene Amplification Technology Market

Syndex Bio revealed its novel mcPCR (methyl-copying PCR) platform at the Advances in Genome Biology and Technology conference in Orlando, Florida. With this groundbreaking technology, the copying of DNA methylation patterns as well as genetic sequences during amplification becomes feasible and with high fidelity- a long-standing limitation of the conventional PCR technique.

The Cambridge-based biotech company has raised $15.5 million in oversubscribed seed funds, led by ARCH Venture Partners and funded by +ND capital, OMX Ventures, and Meltwind. Traditional PCR methods cannot recapitulate DNA methylation patterns, which are important disease biomarkers, including those related to cancer. mcPCR has the potential to become a truly disruptive molecular diagnostic method.

Funding to Support Platform Expansion

The capital raised will help scale the mcPCR platform. It will also be used to create clinical workflows and enhance R&D in Cambridge. The company has established a board with Gautam Kollu, Patrick Weiss, Geoff Smith, Sean Kendall, and Eric Moessinger.

Kollu emphasized that mcPCR breaks down long-standing technical hurdles in epigenetics, making it accessible to those areas of high value in the molecular diagnostics market, of which sensitivity has been historically a constraint.

Clinical Applications in Development

The site is now being constructed to be utilized in cancer screening, chronic diseases, and research that should precisely analyze DNA methylation. The sensitivity of detection can be increased significantly in McPCR and low-volume samples in particular since the pattern of methylation can be amplified.

According to Precedence Research, the Gene Amplification Technology Market size was calculated at USD 3.60 billion in 2025 and is predicted to increase from USD 3.99 billion in 2026 to approximately USD 10.04 billion by 2035, expanding at a CAGR of 10.80% from 2026 to 2035. The need to have advanced molecular diagnostics, early disease diagnosis, and precision medicine stimulates the increase.

Industry Impact and Outlook

The advent of mcPCR suggests a broader trend within the life sciences community of enhanced diagnostic sensitivity and expanded opportunities to access genetic and epigenetic analysis. The use of new technologies, including new techniques in mcPCR, will also play a significant role in early diagnosis of diseases, patient outcomes, and the enhancement of personalized medicine.